Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 2, 1998, Pages 89-92

  Lehne, G ^a   De Angelis, P ^a   Clausen, O P F ^a   Rugstad, H E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; GLYCOPROTEIN P; VALSPODAR;

CELL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TRANSPORT; HEPATOMA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION;

ACLARUBICIN; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CYCLOSPORINS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0031964452     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M et al 1995 Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385
2. Beppu T, Ohara C, Yamaguchi Y, Ichihara T, Yamanaka T, Katafuchi S, Ikei S, Mori K, Fukushima S, Nakano M et al 1991 A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68: 2555-2560
3. Chan HS, DeBoer G, Haddad G, Gallie BL, Ling V 1995 Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 9: 275-318
4. Coley HM, Twentyman PR, Workman P 1989 Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug-resistant cell lines alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 38: 4467-4475
5. Coley HM, Twentyman PR, Workman P 1992 Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. Anticancer Drug Des 7: 471-481
6. Coley HM, Twentyman PR, Workman P 1993 The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol 46: 1317-1326
7. Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bourut C, Mathe G 1979 Electron-microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin detorubicin AD-32 and aclacinomycin. Cancer Treat Rep 63:d 875-888
8. Endicott JA, Ling V 1989 The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171
9. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC 1984 Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 54: 970-977
10. Hall KS, Endresen L, Huitfeldt HS, Rugstad HE 1991 Induction of in vitroresistance to 4'-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells. Anticancer Res 11: 817-823
11. Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H 1977 Antitumor activity of new anthracycline antibiotics aclacinomycin-A and its analogs and their toxicity. Gann 68: 685-690
12. Ichihara T, Sakamoto K, Mori K, Akagi M 1989 Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res 49: 4357-4362
13. Itsubo M, Ishikawa T, Toda G, Tanaka M 1994 Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 73: 298-303
14. Lehne G, De Angelis P, Clausen OP, Egeland T, Tsuruo T, Rugstad HE 1995 Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry 20: 228-237
15. Lehne G, De Angelis P, Clausen OPF, Rugstad HE 1996 Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer 74: 1719-1729
16. Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, de Vassal F, Tapiero H, Ribaud P, Schwarzenberg L et al 1984 Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat Rep 68: 881-886
17. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R 1996 MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 32: 1034-1038
18. Mortensen SA 1987 Aclarubicin: preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines. Eur J Haematol 47 (Suppl): 21-31
19. Oki T, Takeuchi T, Oka S, Umezawa H 1981 New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Results Cancer Res 76: 21-40
20. Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI 1984 Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep 68: 1233-1238
21. Ripamonti M, Capolongo L, Melegaro G, Gornati C, Bargiotti A, Caruso M, Grandi M, Suarato A 1996 Morpholinyl anthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Invest New Drugs 14: 139-146
22. Scambia G, Panici PB, Contu G, De Vincenzo R, Ferrandina G, Isola G, Maccio A, Mancuso S 1994 Mechanisms and modulation of resistance to anthracyclines (Review). Int J Oncol 4: 951-959
23. Teeter LD, Hsu H-C, Curley SA, Tong MJ, Kuo MJ 1993 Expression of multidrug resistance (P-glycoprotein) MDR1 and MDR2 genes in human hepatocellular carcinomas and liver metastases of colonic tumors. Int J Oncol 2: 73-80
24. Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T 1996 Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn J Cancer Res 87: 184-193
25. Yuen AR, Sikic BI 1994 Multidrug resistance in lymphomas. J Clin Oncol 12: 2453-2459